Fully Automated Fluorescent in situ Hybridization (FISH) Staining and Digital Analysis of HER2 in Breast Cancer: A Validation Study

HER2 assessment is routinely used to select patients with invasive breast cancer that might benefit from HER2-targeted therapy. The aim of this study was to validate a fully automated in situ hybridization (ISH) procedure that combines the automated Leica HER2 fluorescent ISH system for Bond with supervised automated analysis with the Visia imaging D-Sight digital imaging platform. HER2 assessment was performed on 328 formalin-fixed/paraffin-embedded invasive breast cancer tumors on tissue microarrays (TMA) and 100 (50 selected IHC 2+ and 50 random IHC scores) full-sized slides of resections/biopsies obtained for diagnostic purposes previously. For digital analysis slides were pre-screened at 20x and 100x magnification for all fluorescent signals and supervised-automated scoring was performed on at least two pictures (in total at least 20 nuclei were counted) with the D-Sight HER2 FISH analysis module by two observers independently. Results were compared to data obtained previously with the manual Abbott FISH test. The overall agreement with Abbott FISH data among TMA samples and 50 selected IHC 2+ cases was 98.8% (κ = 0.94) and 93.8% (κ = 0.88), respectively. The results of 50 additionally tested unselected IHC cases were concordant with previously obtained IHC and/or FISH data. The combination of the Leica FISH system with the D-Sight digital imaging platform is a feasible method for HER2 assessment in routine clinical practice for patients with invasive breast cancer.

[1]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[2]  Caroline Diorio,et al.  Validation of a new classifier for the automated analysis of the human epidermal growth factor receptor 2 (HER2) gene amplification in breast cancer specimens , 2013, Diagnostic Pathology.

[3]  John M S Bartlett,et al.  Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. von Melchner,et al.  Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase. , 1996, Oncogene.

[5]  H. Netten,et al.  FISH and chips: automation of fluorescent dot counting in interphase cell nuclei. , 1997, Cytometry.

[6]  Ioannis Pitas,et al.  Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases. , 2008, Breast.

[7]  M. Dietel,et al.  Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH) , 2008, Diagnostic pathology.

[8]  L. Holmberg,et al.  Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  D. Slamon,et al.  HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  J Lundin,et al.  A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals , 2007, Journal of Clinical Pathology.

[11]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Ullrich,et al.  Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[13]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Norton,et al.  Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. , 1998, Cancer research.

[15]  A. Del Bimbo,et al.  Accurate evaluation of HER-2 amplification in FISH images , 2010, 2010 IEEE International Conference on Imaging Systems and Techniques.

[16]  A. V. D. van den Brule,et al.  Detection of HER2 Amplification in Breast Carcinomas: Comparison of Multiplex Ligation-Dependent Probe Amplification (MLPA) and Fluorescence In Situ Hybridization (FISH) combined with Automated Spot Counting , 2006, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[17]  P. V. van Diest,et al.  Validation of a Fully Automated HER2 Staining Kit in Breast Cancer , 2010, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[18]  L. Goldstein,et al.  HER-2 testing in breast cancer using parallel tissue-based methods. , 2004, JAMA.

[19]  S. Nielsen,et al.  Testing HER2 in Breast Cancer: A Comparative Study on BRISH, FISH, and IHC , 2011, Applied immunohistochemistry & molecular morphology : AIMM.

[20]  J. Ferlay,et al.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. , 2013, European journal of cancer.

[21]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.

[22]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[23]  W. Jochum,et al.  Comparison of automated and manual FISH for evaluation of HER2 gene status on breast carcinoma core biopsies , 2013, BMC Clinical Pathology.

[24]  John M S Bartlett,et al.  HER2 testing: current status and future directions. , 2014, Cancer treatment reviews.

[25]  K. Goddard,et al.  Utilization of HER2 genetic testing in a multi-institutional observational study. , 2012, The American journal of managed care.

[26]  M. Owens,et al.  HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. , 2004, Clinical breast cancer.

[27]  A. Ullrich,et al.  p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor , 1989, Molecular and cellular biology.

[28]  M. J. van de Vijver,et al.  Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach , 2012, Breast Cancer Research.

[29]  D. Alpár,et al.  State‐of‐the‐art FISHing: Automated analysis of cytogenetic aberrations in interphase nuclei , 2012, Cytometry. Part A : the journal of the International Society for Analytical Cytology.